Table 1 Selected inclusion and exclusion criteria
Inclusion Criteria | Exclusion Criteria |
|---|---|
Aged ≥ 18 years Diagnosis of PsA for ≥ 6 months prior to first study intervention administration and meet CASPAR criteria at screening Active PsA: ≥ 3 swollen joints, ≥ 3 tender joints, and CRP ≥ 0.3 mg/dL Inadequate efficacy and or/ intolerance to TNFi therapy: active PsA despite previous treatment with one prior TNFi Active plaque psoriasis (≥ 1 plaque of ≥ 2 cm and/or psoriatic nail changes) or documented history of psoriasis  ≥ 1 of the following PsA subtypes: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis | Other inflammatory diseases (e.g., RA, AS, lupus)  > 1 prior TNFi Prior TNFi within 8 weeks (infliximab, intravenous golimumab), within 6 weeks (subcutaneous golimumab, adalimumab, or certolizumab pegol), or within 4 weeks (etanercept) of first study intervention administration Previous biologic therapy other than one TNFi Previous JAK inhibitor therapy Prior therapy with systemic immunosuppressants; epidural, intra-articular, intramuscular, or intravenous corticosteroids, including adrenocorticotropic hormone; or apremilast within 4 weeks of first study intervention administration Receiving ≥ 2 csDMARDs at baseline |